ResMed Inc. RMD
236.26 USD +0.96 (+0.41%)
Nov 9, 2026, 2:32 PM EST
231.31 Day range 237.84
180.27 52-week range 277.67
- YTD
- -1.91%
- 1 year
- -6.06%
News
barrons.com Don't Lose Sleep Over GLP-1s: Why ResMed Is a Bargain ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
fool.com ResMed: 3 Key Takeaways for Long-Term Investors ResMed reported that core constant currency revenue grew 7% in the first quarter. Patients on GLP-1 drugs are 11% more likely to start CPAP therapy.
benzinga.com Citigroup Maintains Neutral on ResMed, Raises Price Target to $270 Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Neutral and raises the price target from $240 to $270.
benzinga.com RBC Capital Maintains Outperform on ResMed, Raises Price Target to $288 RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.
benzinga.com Wells Fargo Maintains Equal-Weight on ResMed, Raises Price Target to $250 Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.
benzinga.com Keybanc Maintains Overweight on ResMed, Raises Price Target to $277 Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $267 to $277.
benzinga.com ResMed Q1 2027 Earnings Call Transcript ResMed (NYSE:RMD) reported first-quarter financial results on Thursday. The transcript from the company’s first-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com ResMed Sees FY2027 Adj EPS $12.00-$12.25 vs $12.09 Est; Sees Sales $5.750B-$5.850B vs $5.814B Est ResMed (NYSE:RMD) is looking for FY2027 Adj EPS of $12.00-$12.25 vs $12.09 analyst estimate. sees sales of $5.750 billion-$5.850 billion vs $5.814 billion analyst estimate.
benzinga.com ResMed Q1 Adj. EPS $2.91 Beats $2.67 Estimate, Sales $1.415B Beat $1.392B Estimate ResMed (NYSE:RMD) reported quarterly earnings of $2.91 per share which beat the analyst consensus estimate of $2.67 by 8.99 percent. This is a 14.12 percent increase over earnings of $2.55 per share…
benzinga.com If You Invested $1000 In ResMed Stock 20 Years Ago, You Would Have This Much Today ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 3.82% on an annualized basis producing an average annual return of 12.81%. Currently, ResMed has a market capitalization of…
benzinga.com ResMed Q4 2026 Earnings Call Transcript ResMed (NYSE:RMD) reported fourth-quarter financial results on Thursday. The transcript from the company's fourth-quarter earnings call has been provided below. Benzinga APIs provide real-time access…
benzinga.com Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7% Stocks fell and small caps slumped Wednesday as the 30-year Treasury yield hit 5.7%, a 24-year high, with Fed minutes and bond auctions ahead.
benzinga.com RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262 RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.
benzinga.com Keybanc Maintains Overweight on ResMed, Raises Price Target to $267 Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $255 to $267.- benzinga.com Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230 Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.
benzinga.com RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244 RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.- benzinga.com Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225 Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.
- benzinga.com Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255 Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.
- benzinga.com Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215 Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $225 to $215.
benzinga.com Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.- benzinga.com ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.89 by 2.08 percent. This is a 15.69 percent increase over earnings of $2.55 per share…
- benzinga.com Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220 Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $235 to $220.
benzinga.com Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.- benzinga.com Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235 Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the price target from $270 to $235.
- benzinga.com Jefferies Maintains Hold on ResMed, Lowers Price Target to $225 Jefferies analyst Matthew Taylor maintains ResMed (NYSE:RMD) with a Hold and lowers the price target from $240 to $225.
benzinga.com ResMed Analyst Backs Portfolio Reset ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh near-term EPS dilution against long-term growth.- benzinga.com RBC Capital Maintains Outperform on ResMed, Lowers Price Target to $276 RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $321 to $276.
- benzinga.com Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $225 Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $227 to $225.
- benzinga.com ResMed Says Deal Valued At $490M All-Cash, Expected To Close In Q1 FY2027 On July 7, 2026, ResMed Inc. (the "Company" or "Resmed") issued a press release announcing that on June 30, 2026 it entered into a definitive agreement to sell its MatrixCare business to Frazier
- benzinga.com Resmed Strikes Agreement To Sell Its MatrixCare Operations To Frazier Healthcare Partners; Financial Terms Undisclosed Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its…
- benzinga.com Keybanc Maintains Overweight on ResMed, Lowers Price Target to $266 Keybanc analyst Justin Patterson maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $290 to $266.
benzinga.com Here’s How Much You Would Have Made Owning ResMed Stock In The Last 20 Years ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 1.89% on an annualized basis producing an average annual return of 11.28%. Currently, ResMed has a market capitalization of…
benzinga.com Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.
benzinga.com This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, initiations. See opinions on EFC stock.
benzinga.com Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J B Hunt, Needham for Glaukos, B of A for CSX, Morgan Stanley for Charles River, and Bernstein for…- benzinga.com Morgan Stanley Downgrades ResMed to Equal-Weight, Lowers Price Target to $230 Morgan Stanley analyst David Bailey downgrades ResMed (NYSE:RMD) from Overweight to Equal-Weight and lowers the price target from $286 to $230.
- benzinga.com ResMed Acquires Sleep-Related Wearables Developer Noctrix Health From Angelini Industries For $340M Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company…
benzinga.com Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now And 1999 Is...' Jim Cramer says investors are aggressively favoring AI stocks while heavily punishing companies that disappoint Wall Street.- benzinga.com RBC Capital Maintains Outperform on ResMed, Raises Price Target to $321 RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $314 to $321.
- benzinga.com Transcript: ResMed Q3 2026 Earnings Conference Call
- benzinga.com Resmed Appoints Aaron Bloomer CFO, Succeeding Brett Sandercock Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans…
- benzinga.com ResMed Q3 Adj. EPS $2.86 Beats $2.80 Estimate, Sales $1.431B Beat $1.419B Estimate ResMed (NYSE:RMD) reported quarterly earnings of $2.86 per share which beat the analyst consensus estimate of $2.80 by 2.14 percent. This is a 20.68 percent increase over earnings of $2.37 per share…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Keybanc Maintains Overweight on ResMed, Lowers Price Target to $290 Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $302 to $290.
- benzinga.com Citigroup Maintains Buy on ResMed, Lowers Price Target to $340 Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Buy and lowers the price target from $345 to $340.
- benzinga.com Here's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years
- benzinga.com Here's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years
benzinga.com Disney, Toast, ServiceNow And A Health Care Stock On CNBC's 'Final Trades' Joshua Brown of Ritholtz Wealth Management likes Toast, and Sarat Sethi is sticking with Disney; Malcolm Ethridge chooses ServiceNow.- benzinga.com Resmed Opening New Distribution Site In Greenwood, Indiana Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled…
benzinga.com Breaking Down ResMed: 7 Analysts Share Their Views